CHAQ

Chardan Healthcare Acquisition 2 Corp. [CHAQ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CHAQ Stock Summary

In the News

03:08 28 Mar 2024 CHAQ

Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.

04:42 28 Mar 2024 CHAQ

Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants.

03:14 28 Mar 2024 CHAQ

Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021.

07:00 28 Mar 2024 CHAQ

Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance

Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy

02:02 28 Mar 2024 CHAQ

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - CHAQ

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Chardan Healthcare Acquisition 2 Corp. ("CHAQ" or the "Company") (CHAQ) relating to its proposed merger Renovacor, Inc. Under the terms of the agreement, CHAQ will acquire Renovacor through a reverse merger, with Renovacor emerging as a publicly traded company. The investigation focuses on whether Chardan Healthcare Acquisition 2 Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

06:51 28 Mar 2024 CHAQ

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the brakes as we near the election, with just one new IPO filing.

01:20 28 Mar 2024 CHAQ

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings.

07:23 28 Mar 2024 CHAQ

Kamada Ltd. (KMDA) Q2 2019 Earnings Call Transcript | The Motley Fool

KMDA earnings call for the period ending June 30, 2019.

02:29 28 Mar 2024 CHAQ

Why Big Pharma Is Diving Into Gene Therapy

Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors

CHAQ Financial details

Company Rating
Neutral
Market Cap
0
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
-137.87
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
10.78M
Shs Float
1.16M
-
-
-
-
Target Price
-
52W Range
8.1-9.25
52W High
-
52W Low
-
RSI
-
Rel Volume
5.6
Avg Volume
43.34K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
3.1%, 3.1%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
Same Sector
Similar Market Cap